Frankfurt - Delayed Quote ? EUR Tevogen Bio Holdings Inc. (G28.F) Follow Compare 2.3000 -0.0200 (-0.86%) At close: November 1 at 7:23 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs Current timeline for drug development is 10-12 years and costs approximately $1-3 billion. Tevogen’s approach has the potential to shorten timelines and substantially reduce costs. Tevogen’s AI initiative, Tevogen.AI, will pursue two key objectives, applying machine learning to existing processes to accelerate drug development and lower costs, and using Microsoft’s industry leading AI tools to develop proprietary algorithms designed to decode the relationship between genetics and T cells. WARREN GlobeNewswire ? yesterday MSFT TVGN TVGNW Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company Regained compliance without effecting a reverse stock splitTevogen Bio CEO reaffirms his commitment to preserve shareholder value WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that on October 28, 2024, it received written notice from the Listing Qualif GlobeNewswire ? 3 days ago TVGN TVGNW MSFT Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity CD8 Technology Services, LLC (“CD8 Technology”) to provide turn-key facility for Tevogen BioReinforces Tevogen Bio’s commitment to preserving shareholder valueExpected to further enhance Tevogen Bio’s ambitious growth agenda WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancer GlobeNewswire ? 3 days ago TVGN TVGNW Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of the company’s proprietary ExacTcell? technology, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised oncology patients, and a subgroup GlobeNewswire ? 7 days ago TVGN TVGNW Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development WARREN, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (Nasdaq: MSFT) for Startups. This partnership marks a significant milestone for Tevogen, providing unparalleled access to Microsoft’s extensive GlobeNewswire ? 9 days ago TVGN TVGNW MSFT Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to provide further updates on the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas by the end of this week. The revenue forecast for the two therapeutic areas is GlobeNewswire ? 10 days ago TVGN TVGNW Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years. WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers GlobeNewswire ? 11 days ago TVGN TVGNW Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, reported last week that Chief Scientific Officer (CSO) Dr. Neal Flomenberg sold shares. Tevogen's Chief Financial Officer, Kirti Desai, clarified that the sale was made solely to satisfy the payment of tax obligations rela GlobeNewswire ? 11 days ago TVGN TVGNW Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell? technology, designed to create accessible GlobeNewswire ? 13 days ago TVGN TVGNW Tevogen Bio Oncology Reports Top-Line Revenue Forecast of?$1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success through patient accessibility. WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and GlobeNewswire ? 15 days ago TVGN TVGNW Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare ventures, congratulate Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) and founding CEO Dr. Ryan Saadi for being honored with prestigious proclamation by the Township of Warren, New Jersey, in recognition of their Nobel Prize nomination for pioneering business model to alleviate health inequality through breakthrough life-saving medical innovatio GlobeNewswire ? 15 days ago TVGN TVGNW Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality WARREN, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, expresses its heartfelt gratitude to the Township of Warren and its leadership for the recent proclamation honoring Tevogen’s efforts to address health inequality and the Nobel Peace Prize nomination of its CEO and founder GlobeNewswire ? 16 days ago TVGN TVGNW Tevogen Bio Takes Lead in Developing Cell Therapies Designed to?Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions Approximately one in three women remain HPV positive after cervical procedures for precancerous lesions.Tens of thousands of women in the US each year are diagnosed with high-grade cervical precancerous lesions.These high-grade cervical lesions can reoccur, requiring more treatment, and potentially lead to cervical cancer.Nearly all cervical cancer and high-grade cervical lesions are associated with HPV which promotes cancer formation.The primary risk factor for the recurrence of high-grade cerv GlobeNewswire ? 17 days ago TVGN TVGNW Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use WARREN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today highlights the publication of its phase I clinical trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy, published by the journal Blood Advances GlobeNewswire ? 17 days ago TVGN TVGNW Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation following this week’s $1b+ revenue potential announcement. “Our shareholders have placed their trust in us, and that is a privilege we take with the utmo GlobeNewswire ? 18 days ago TVGN TVGNW Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to share its $1B+ revenue potential, a reflection of the company’s novel business approach. “In the current market reality, Tevogen Bio’s unique, faster, and cost-efficient drug development model has the potential to GlobeNewswire ? 21 days ago TVGN TVGNW Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Expanding its pipeline to include non-oncology products, an opportunistic approach aimed at maximizing ROI from its ExacTcell? technology. WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) GlobeNewswire ? 21 days ago TVGN TVGNW Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level. Endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were met. Fifty percent (50%) of treatment arm patients were immunocompromised versus six percent (6%) of observational arm patients. Treatment arm patient GlobeNewswire ? 24 days ago TVGN TVGNW Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shared the company’s ambition to address the Long COVID crisis as its leadership met with Congress on Capitol Hill last week. “It was an honor to meet with congressional teams in Washington, D.C., to address the urgent ch GlobeNewswire ? last month TVGN TVGNW Tevogen Bio Secures $6 Million Series C Preferred Stock Investment WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payabl GlobeNewswire ? 2 months ago TVGN TVGNW Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return G28.F S&P 500 YTD -73.40% +14.45% 1-Year -73.40% +14.45% 3-Year -73.40% +14.45%
